NCT05741294

A Study of Tirbanibulin on the Wellbeing of Participants With Actinic Keratoses

Open Phase IV Study to Assess the Impact of Tirbanibulin on the Wellbeing of Patients With Actinic Keratoses (TIRBASKIN)

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 334 (actual)
• Sponsor: Almirall, S.A. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to assess treatment satisfaction on Day 57 in participants with Actinic Keratoses (AK) of the face or scalp following treatment with tirbanibulin ointment 1 percent (%) administered once daily for 5 consecutive days.

Conditions

• Actinic Keratosis

Interventions

Type	Name	Description
DRUG	Tirbanibulin 2.5 mg ointment	Participants will apply tirbanibulin 2.5 mg ointment topically for 5 consecutive days over 25 square centimeters (cm\^2) of the face or scalp.

Timeline

• Start date: 2023-01-20
• Primary completion: 2024-01-19
• Completion: 2024-01-19
• First posted: 2023-02-23
• Last updated: 2025-02-20
• Results posted: 2025-02-20

Locations

37 sites across 2 countries: Italy, Spain